Natera, Inc. Common Stock
NTRANatera, Inc. is a biotechnology company specializing in genetic testing and diagnostics. It develops and offers advanced cell-free DNA testing services for reproductive health, oncology, organ transplant monitoring, and rare disorders. Natera's innovative approach includes non-invasive prenatal testing (NIPT) and other laboratory-based genetic assays to help clinicians and patients make informed medical decisions.
Company News
William Blair initiated coverage on Natera (NASDAQ: NTRA), highlighting the company's strong positioning in the minimal residual disease (MRD) testing market. Analyst Andrew Brackmann estimates Natera generated close to $1 billion in MRD revenue in 2025 with expected growth exceeding 40% in 2026. The MRD market, valued at over $20 billion, is sti...
Natera announced promising results from a prospective study showing its Signatera molecular residual disease (MRD) test can identify older women with early-stage ER+/HER2- breast cancer who can be managed with primary endocrine therapy without surgery. The study of 43 women over 70 demonstrated 100% negative predictive value for MRD-negative pati...
Exelixis, a U.S.-based biotech company specializing in cancer treatments, is positioned for market-beating returns through its growing pipeline beyond its blockbuster cabozantinib drug. The company reported 57.9% EPS growth in 2025 and recently received FDA approval for zanzalintinib for metastatic colorectal cancer. With zanzalintinib in four ph...
Billionaire investor Stanley Druckenmiller holds two major positions in his portfolio: Natera (NTRA), a genetic testing company with strong revenue growth and expanding margins despite current losses, and Taiwan Semiconductor Manufacturing (TSM), which benefits from AI demand but faces challenges with rising capital expenditures that will limit f...
The global esoteric testing market is projected to grow from $27.52 billion in 2025 to $41.56 billion by 2031 at a 7.11% CAGR, driven by rising chronic disease rates, personalized medicine demand, and liquid biopsy adoption. However, stringent regulatory frameworks and reimbursement pressures pose significant challenges to market expansion.
